Premium
Pharmacokinetics of a novel eicosapentaenoic acid derived anti‐leukemic prostaglandin, Δ 12 ‐ prostaglandin J3 in a murine model
Author(s) -
Kudva Avinash Kundadka,
Kaushal Naveen,
Paulson Robert F,
Prabhu Sandeep K
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.636.14
Subject(s) - eicosapentaenoic acid , polyunsaturated fatty acid , pharmacokinetics , pharmacology , prostaglandin , arachidonic acid , chemistry , in vivo , cancer research , biochemistry , medicine , fatty acid , biology , microbiology and biotechnology , enzyme
Cyclopentenone prostaglandins are downstream metabolites of prostaglandin D series that exhibit anti‐inflammatory and anti‐carcinogenic activities. Recently, our laboratory has shown that Δ 12 ‐prostaglandin J 3 (Δ 12 ‐PGJ 3 ), produced from dietary omega‐3 polyunsaturated fatty acid (n‐3 PUFA), eicosapentaenoic acid (EPA), alleviates the progression of leukemia in three murine models with a remarkable selectivity towards leukemia stem cells (LSC), but not the normal hematopoietic stem cells (HSC). In the present study, we have evaluated the stability and pharmacokinetic properties of Δ 12 ‐PGJ 3 in vivo models to establish efficacy and toxicology profile enabling better therapeutic strategies in the future. These studies should have a bearing on the nutritional intervention strategies using EPA‐rich diets in the above models of the disease. Grant Funding Source : NIH